Correlations between serum interleukin 6, serum soluble interleukin 6 receptor, and disease activity in systemic juvenile idiopathic arthritis patients treated with or without tocilizumab
| العنوان: | Correlations between serum interleukin 6, serum soluble interleukin 6 receptor, and disease activity in systemic juvenile idiopathic arthritis patients treated with or without tocilizumab |
|---|---|
| المؤلفون: | Butsabong Lerkvaleekul, Supranee Buranapraditkun, Chavachol Setthaudom, Sirisucha Soponkanaporn, Soamarat Vilaiyuk |
| المصدر: | Central-European Journal of Immunology Central European Journal of Immunology, Vol 44, Iss 2, Pp 150-158 (2019) |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | medicine.medical_specialty, systemic juvenile idiopathic arthritis, anti-interleukin 6 receptor antibody, Immunology, Arthritis, lcsh:Medicine, interleukin 6, Gastroenterology, Proinflammatory cytokine, chemistry.chemical_compound, tocilizumab, Tocilizumab, Internal medicine, Immunology and Allergy, Medicine, Receptor, Interleukin 6, interleukin 6 receptor, biology, business.industry, lcsh:R, Interleukin, medicine.disease, chemistry, correlation, Interleukin-6 receptor, biology.protein, juvenile idiopathic arthritis, Clinical Immunology, Antibody, business |
| الوصف: | Introduction Interleukin (IL)-6 is a proinflammatory cytokine involved in systemic juvenile idiopathic arthritis (SJIA). Since these patients are often treated with tocilizumab (TCZ), anti-IL-6 receptor (IL-6R) antibody, we investigated correlations between serum IL-6 and soluble IL-6R-levels and disease activity in SJIA patients treated with or without TCZ. Material and methods 164 serum samples were taken from 42 SJIA patients treated with or without TCZ (69 and 95 samples, respectively). Patients were assigned to three groups according to disease status: 1) systemic (patients with systemic features and/or arthritis), 2) arthritis (patients with arthritis but no systemic features), and 3) inactive (clinically inactive disease). Disease activity was assessed using the Juvenile Arthritis Disease Activity Score-27 (JADAS-27) at the time of blood collection. Results IL-6 levels were highest in SJIA patients with predominant systemic features, while serum sIL-6R levels were highest in patients with persistent arthritis. Serum IL-6 correlated with JADAS-27 in patients treated with and without TCZ (r = 0.38 and r = 0.65, respectively), whereas serum sIL-6R levels correlated with JADAS-27 in patients treated without (r = 0.30) but not with (r = -0.14) TCZ. The sIL-6R/IL-6 ratio negatively correlated with JADAS-27 in patients treated with and without TCZ (r = -0.49 and r = -0.56, respectively). Conclusions Serum IL-6 levels correlated more strongly with disease activity parameters than did sIL-6R levels and could be useful for monitoring disease activity in SJIA patients. The sIL-6R/IL-6 ratio might be a promising disease activity marker in both SJIA patients treated with and without TCZ. |
| تدمد: | 1426-3912 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::316344e99b8d000412b5082867a24302Test https://pubmed.ncbi.nlm.nih.gov/31530985Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....316344e99b8d000412b5082867a24302 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14263912 |
|---|